Allogeneic Umbilical Cord Mesenchymal Stem Cell not checked

PT. Prodia Stem Cell Indonesia

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“All research samples will be treated by Intravenous injection of allogeneic mesenchymal stem cells and hemodynamic observation will be done for 24 hours after treated. Periodic post-treatment observation will be done on 1st month, 3rd month, and 6th month after therapy. The Independent variable in this research is Child-Pugh B Cirrhosis caused by Hepatitis B, while the dependent variable is the…”In the company’s words, NCT04357600 on ClinicalTrials.gov
Tested for
Liver Cirrhoses
Main trialPhase 1/2
“The study aims to evaluate the effect of allogeneic mesenchymal stem cell therapy on patients who suffered from liver cirrhosis caused by Hepatitis B.”In the company’s words, NCT04357600 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Enrolling by invitation 20 Jun 2027 Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Allogeneic Umbilical Cord Mesenchymal Stem Cell

Following is part of Solo: you see every change to Allogeneic Umbilical Cord Mesenchymal Stem Cell the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in